OpenAI launches GPT-Rosalind for drug discovery and life sciences research

OpenAI introduced GPT-Rosalind, a specialized AI model designed to accelerate drug discovery and life sciences research by analyzing large datasets and translating scientific studies into healthcare applications. The model is initially available as a research preview to select business customers including Amgen, Moderna, and the Allen Institute, directly competing with Anthropic's life sciences initiatives.